Pyrrolo[1,2-b]pyridazin-2-ones as potent inhibitors of HCV NS5B polymerase
作者:Frank Ruebsam、Stephen E. Webber、Martin T. Tran、Chinh V. Tran、Douglas E. Murphy、Jingjing Zhao、Peter S. Dragovich、Sun Hee Kim、Lian-Sheng Li、Yuefen Zhou、Qing Han、Charles R. Kissinger、Richard E. Showalter、Matthew Lardy、Amit M. Shah、Mei Tsan、Rupal Patel、Laurie A. LeBrun、Ruhi Kamran、Maria V. Sergeeva、Darian M. Bartkowski、Thomas G. Nolan、Daniel A. Norris、Leo Kirkovsky
DOI:10.1016/j.bmcl.2008.04.066
日期:2008.6
Pyrrolo[1,2-b]pyridazin-2-one analogs were discovered as a novel class of inhibitors of genotype 1 HCV NS5B polymerase. Structure-based design led to the discovery of compound 3 k, which displayed potent inhibitory activities in biochemical and replicon assays (IC(50) (1b)<10nM; EC(50) (1b)=12 nM) as well as good stability towards human liver microsomes (HLM t(1/2)>60 min).
The invention is directed to pyrro[1,2-b]pyridazinone compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.
The invention is directed to pyrro[1,2-b]pyridazinone compounds of Formula I and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus:
wherein R4 is selected from
Ring A is 5 or 6- membered aryl or heterocyclyl, and the remaining substituents are defined herein.